JP2019529574A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529574A5 JP2019529574A5 JP2019538720A JP2019538720A JP2019529574A5 JP 2019529574 A5 JP2019529574 A5 JP 2019529574A5 JP 2019538720 A JP2019538720 A JP 2019538720A JP 2019538720 A JP2019538720 A JP 2019538720A JP 2019529574 A5 JP2019529574 A5 JP 2019529574A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- use according
- subject
- treatment
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 24
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 10
- 238000009472 formulation Methods 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims 6
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims 6
- 229940028334 follicle stimulating hormone Drugs 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 210000002966 serum Anatomy 0.000 claims 5
- 229960003604 testosterone Drugs 0.000 claims 5
- 238000012423 maintenance Methods 0.000 claims 4
- 125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 claims 2
- 239000003163 gonadal steroid hormone Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 claims 2
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 claims 1
- 206010071119 Hormone-dependent prostate cancer Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 238000011292 agonist therapy Methods 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960004671 enzalutamide Drugs 0.000 claims 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662402004P | 2016-09-30 | 2016-09-30 | |
| US201662402150P | 2016-09-30 | 2016-09-30 | |
| US62/402,150 | 2016-09-30 | ||
| US62/402,004 | 2016-09-30 | ||
| PCT/EP2017/074849 WO2018060463A2 (en) | 2016-09-30 | 2017-09-29 | Treatment of prostate cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529574A JP2019529574A (ja) | 2019-10-17 |
| JP2019529574A5 true JP2019529574A5 (enExample) | 2020-11-12 |
| JP7062673B2 JP7062673B2 (ja) | 2022-05-06 |
Family
ID=60915459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538720A Active JP7062673B2 (ja) | 2016-09-30 | 2017-09-29 | 前立腺がんの治療 |
Country Status (21)
| Country | Link |
|---|---|
| US (8) | US10449191B2 (enExample) |
| EP (2) | EP3518932B1 (enExample) |
| JP (1) | JP7062673B2 (enExample) |
| CN (1) | CN110248661A (enExample) |
| AU (2) | AU2017334035B2 (enExample) |
| BR (1) | BR112019006228A2 (enExample) |
| CA (1) | CA3038875A1 (enExample) |
| DK (1) | DK3518932T3 (enExample) |
| ES (1) | ES3002857T3 (enExample) |
| FI (1) | FI3518932T3 (enExample) |
| HR (1) | HRP20241740T1 (enExample) |
| HU (1) | HUE070578T2 (enExample) |
| IL (3) | IL308528A (enExample) |
| LT (1) | LT3518932T (enExample) |
| MA (1) | MA46361A (enExample) |
| MX (2) | MX2019003733A (enExample) |
| NZ (1) | NZ752918A (enExample) |
| PL (1) | PL3518932T3 (enExample) |
| PT (1) | PT3518932T (enExample) |
| SI (1) | SI3518932T1 (enExample) |
| WO (1) | WO2018060463A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20190729T1 (hr) | 2012-09-28 | 2019-06-14 | Takeda Pharmaceutical Company Limited | Metoda proizvodnje derivata tienopirimidina |
| WO2018060501A2 (en) | 2016-09-30 | 2018-04-05 | Myovant Sciences Gmbh | Methods of treating uterine fibroids and endometriosis |
| EP3518932B1 (en) | 2016-09-30 | 2024-11-13 | Sumitomo Pharma Switzerland GmbH | Treatment of prostate cancer |
| CN110194776B (zh) * | 2019-06-27 | 2021-05-28 | 四川伊诺达博医药科技有限公司 | 一种瑞卢戈利的合成方法 |
| EP4041738A1 (en) * | 2019-10-10 | 2022-08-17 | Myovant Sciences GmbH | Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| CN115279769A (zh) * | 2019-10-10 | 2022-11-01 | 梦欧文科学有限责任公司 | N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式 |
| AU2021278303A1 (en) | 2020-05-29 | 2023-02-09 | Sumitomo Pharma Switzerland Gmbh | Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists |
| US20230384316A1 (en) * | 2020-10-20 | 2023-11-30 | Baylor College Of Medicine | Multiplex metabolic markers in plasma for early detection of african american prostate cancer |
| EP4243829A1 (en) * | 2020-11-11 | 2023-09-20 | Myovant Sciences GmbH | Methods of administering relugolix |
| WO2023066941A1 (en) | 2021-10-18 | 2023-04-27 | Myovant Sciences Gmbh | Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| WO2023152611A1 (en) * | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide and relugolix for the treatment of prostate cancer |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2710637B1 (fr) | 1993-09-28 | 1995-12-08 | Roquette Freres | Mannitol pulvérulent de friabilité modérée et son procédé de préparation. |
| RU2233284C2 (ru) | 1999-03-24 | 2004-07-27 | Такеда Кемикал Индастриз, Лтд. | Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона |
| TWI225863B (en) | 1999-03-24 | 2005-01-01 | Takeda Chemical Industries Ltd | Thienopyrimidine compounds, their production and use |
| AU2001234188A1 (en) | 2000-02-29 | 2001-09-12 | Takeda Chemical Industries Ltd. | Processes for the production of thienopyrimidine derivatives |
| US20050043315A1 (en) | 2002-01-02 | 2005-02-24 | Hideo Tsutsumi | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them |
| WO2003064429A1 (en) | 2002-01-30 | 2003-08-07 | Takeda Chemical Industries, Ltd. | Thienopyrimidines, process for preparing the same and use thereof |
| DK1480679T3 (da) | 2002-02-26 | 2007-09-03 | Astrazeneca Ab | Farmaceutisk formulering af iressa, der omfatter et vandoplöseligt cellulosederivat |
| KR101074462B1 (ko) | 2003-01-29 | 2011-10-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 티에노피리미딘 화합물 및 그 용도 |
| KR101139148B1 (ko) | 2003-07-07 | 2012-04-26 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 고나도트로핀-방출 호르몬 수용체 길항제로서의피리미딘-2,4-디온 유도체 |
| NZ566038A (en) | 2005-07-22 | 2011-06-30 | Takeda Pharmaceutical | The use of thieno(2,3-d)pyrimidine-2,4-dione derivatives which are gonadotropin releasing hormone (GnRH) antagonists as premature ovulation preventive agent |
| ES2534573T3 (es) | 2007-04-06 | 2015-04-24 | Neurocrine Biosciences, Inc. | Antagonistas del receptor de la hormona liberadora de gonadotropina y métodos relacionados con los mismos |
| US8765948B2 (en) | 2007-11-07 | 2014-07-01 | Neurocrine Biosciences, Inc. | Processes for the preparation of uracil derivatives |
| JOP20090061B1 (ar) | 2008-02-11 | 2021-08-17 | Ferring Int Center Sa | طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH |
| EP2329823A4 (en) | 2008-09-03 | 2013-04-03 | Takeda Pharmaceutical | PROCESS FOR INCREASING THE ABSORPTION ABILITY OF A PREPARATION AND PREPARATION WITH INCREASED ABSORPTION ABILITY |
| HRP20190729T1 (hr) | 2012-09-28 | 2019-06-14 | Takeda Pharmaceutical Company Limited | Metoda proizvodnje derivata tienopirimidina |
| US10821152B2 (en) | 2014-08-26 | 2020-11-03 | Betanien Hospital | Methods, agents and compositions for treatment of inflammatory conditions |
| ES2988678T3 (es) | 2015-02-26 | 2024-11-21 | Takeda Pharmaceuticals Co | Un comprimido que comprende un derivado de metoxiurea y partículas de manitol |
| CA3002791A1 (en) | 2015-09-01 | 2017-03-09 | Abbvie Inc. | Methods of administering elagolix |
| US20180044977A1 (en) | 2016-08-12 | 2018-02-15 | Raynor Mfg. Co. | Rolling door construction for controlling air leakage |
| EP3518932B1 (en) | 2016-09-30 | 2024-11-13 | Sumitomo Pharma Switzerland GmbH | Treatment of prostate cancer |
| WO2018060501A2 (en) | 2016-09-30 | 2018-04-05 | Myovant Sciences Gmbh | Methods of treating uterine fibroids and endometriosis |
-
2017
- 2017-09-29 EP EP17823017.3A patent/EP3518932B1/en active Active
- 2017-09-29 HR HRP20241740TT patent/HRP20241740T1/hr unknown
- 2017-09-29 JP JP2019538720A patent/JP7062673B2/ja active Active
- 2017-09-29 ES ES17823017T patent/ES3002857T3/es active Active
- 2017-09-29 CA CA3038875A patent/CA3038875A1/en active Pending
- 2017-09-29 AU AU2017334035A patent/AU2017334035B2/en active Active
- 2017-09-29 WO PCT/EP2017/074849 patent/WO2018060463A2/en not_active Ceased
- 2017-09-29 SI SI201731574T patent/SI3518932T1/sl unknown
- 2017-09-29 DK DK17823017.3T patent/DK3518932T3/da active
- 2017-09-29 EP EP24212224.0A patent/EP4520398A3/en active Pending
- 2017-09-29 CN CN201780072970.4A patent/CN110248661A/zh active Pending
- 2017-09-29 MX MX2019003733A patent/MX2019003733A/es unknown
- 2017-09-29 HU HUE17823017A patent/HUE070578T2/hu unknown
- 2017-09-29 NZ NZ752918A patent/NZ752918A/en unknown
- 2017-09-29 PT PT178230173T patent/PT3518932T/pt unknown
- 2017-09-29 IL IL308528A patent/IL308528A/en unknown
- 2017-09-29 PL PL17823017.3T patent/PL3518932T3/pl unknown
- 2017-09-29 MA MA046361A patent/MA46361A/fr unknown
- 2017-09-29 IL IL300071A patent/IL300071A/en unknown
- 2017-09-29 LT LTEPPCT/EP2017/074849T patent/LT3518932T/lt unknown
- 2017-09-29 FI FIEP17823017.3T patent/FI3518932T3/fi active
- 2017-09-29 BR BR112019006228A patent/BR112019006228A2/pt not_active Application Discontinuation
-
2019
- 2019-03-28 IL IL265697A patent/IL265697B2/en unknown
- 2019-03-29 MX MX2023001468A patent/MX2023001468A/es unknown
- 2019-03-29 US US16/369,729 patent/US10449191B2/en active Active
- 2019-09-06 US US16/563,161 patent/US10786501B2/en active Active
-
2020
- 2020-08-20 US US16/998,900 patent/US11583526B2/en active Active
-
2022
- 2022-07-15 US US17/866,203 patent/US12097198B2/en active Active
-
2023
- 2023-02-22 AU AU2023201047A patent/AU2023201047B2/en active Active
-
2024
- 2024-06-28 US US18/758,904 patent/US12144809B1/en active Active
- 2024-11-05 US US18/937,891 patent/US12336990B2/en active Active
- 2024-11-25 US US18/959,460 patent/US20250082632A1/en active Pending
-
2025
- 2025-07-09 US US19/264,673 patent/US20250332166A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019529574A5 (enExample) | ||
| FI3518932T3 (fi) | Eturauhassyövän hoito | |
| CN103945849B (zh) | 癌症的联合治疗 | |
| JP2013501731A5 (enExample) | ||
| JP2019167352A (ja) | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター | |
| JP2020529996A5 (enExample) | ||
| US20110124617A1 (en) | Combination Therapy for BreastCancer Comprising an Antiestrogenic Agent | |
| JP2020079320A (ja) | 異常な細胞成長を処置するための方法および組成物 | |
| HUE029677T2 (hu) | Készítmények centrálisan mediált émelygés és hányás kezelésére | |
| TW200942235A (en) | Dosing regimen for a selective S1P1 receptor agonist | |
| JP2019505585A (ja) | ２−ブロモ−１−（３，３−ジニトロアゼチジン−１−イル）エタノンの静脈内投与のための組成物および方法 | |
| JP2015531373A5 (enExample) | ||
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| WO2015185011A1 (zh) | 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物 | |
| TW202333675A (zh) | 用於治療癌症之組合療法之用途 | |
| CN1262622A (zh) | 调节人性反应的联合治疗 | |
| CN107072969B (zh) | 使用顺式氯米芬治疗雄激素剥夺疗法诱导的热潮红和骨丢失 | |
| JP2005531612A (ja) | ネフォパムの製剤および痛みの治療におけるその使用 | |
| JP2019531286A5 (enExample) | ||
| JP2014522414A5 (enExample) | ||
| JP2005513167A5 (enExample) | ||
| CN104968340A (zh) | 治疗肝脏疾病或病状的用途和方法 | |
| RU2017134553A (ru) | Хорошо растворимые в воде соли фенилалкиламина - быстродействующего блокатора кальциевых каналов, и их применение | |
| TW201244732A (en) | Ezatiostat for treating multiple myeloma | |
| CN100402029C (zh) | 包含埃坡霉素衍生物和烷化剂的组合 |